Needham Reiterates Buy on Lucid Diagnostics, Maintains $3 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 87.9%

Neg 0% Neu 87.9% Pos 0%

Needham analyst Mike Matson reiterates Lucid Diagnostics (NASDAQ:LUCD) with a Buy and maintains $3 price target.

Comments

No comments yet. Be the first!